Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial"

Cancer Prev Res (Phila). 2008 Aug;1(3):215-6; author reply 216. doi: 10.1158/1940-6207.CAPR-08-0094.
No abstract available

Publication types

  • Evaluation Study
  • Letter
  • Comment

MeSH terms

  • Adenoma / diagnosis
  • Adenoma / pathology
  • Adenoma / prevention & control*
  • Antineoplastic Agents / therapeutic use
  • Biomarkers* / analysis
  • Celecoxib
  • Chemoprevention / methods
  • Clinical Trials as Topic
  • Colorectal Neoplasms / diagnosis
  • Colorectal Neoplasms / pathology
  • Colorectal Neoplasms / prevention & control*
  • Consensus
  • Early Detection of Cancer
  • Humans
  • Intestinal Mucosa / pathology*
  • Precancerous Conditions / diagnosis*
  • Precancerous Conditions / pathology
  • Pyrazoles / therapeutic use*
  • Sulfonamides / therapeutic use*

Substances

  • Antineoplastic Agents
  • Biomarkers
  • Pyrazoles
  • Sulfonamides
  • Celecoxib